Holen Sie sich die Stockscreener-App
1.72
6.01%
-0.11
Handel nachbörslich:
1.75
0.03
+1.74%
Schlusskurs vom Vortag:
$1.83
Offen:
$1.82
24-Stunden-Volumen:
255.97K
Relative Volume:
1.04
Marktkapitalisierung:
$92.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.39M
KGV:
-2.0476
EPS:
-0.84
Netto-Cashflow:
$-18.45M
1W Leistung:
+3.61%
1M Leistung:
-5.49%
6M Leistung:
+21.13%
1J Leistung:
+198.66%
1-Tages-Spanne:
$1.72
$1.85
1-Wochen-Bereich:
$1.53
$1.93
52-Wochen-Spanne:
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Firmenname
Quince Therapeutics Inc
Sektor
Branche
Telefon
415-910-5717
Adresse
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Vergleichen Sie QNCX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.72 | 85.80M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-03-24 | Eingeleitet | Oppenheimer | Outperform |
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Quince Therapeutics (NASDAQ:QNCX) Price Target Lowered to $8.00 at JMP Securities - Defense World
Is Quince Therapeutics Inc. stock poised for growthWeekly Trading Summary & Weekly Setup with ROI Potential - Newser
How Quince Therapeutics Inc. stock performs during market volatilityEarnings Risk Report & Verified Swing Trading Watchlists - Newser
Is it time to cut losses on Quince Therapeutics Inc.Free Target Return Focused Trade Insights - Newser
What institutional flow reveals about Quince Therapeutics Inc.July 2025 Closing Moves & Momentum Based Trading Signals - Newser
Using RSI to spot recovery in Quince Therapeutics Inc.Algorithmic Forecast for Swing Trading Picks - Newser
Quince Therapeutics Inc. Stock Lags Behind Sector BenchmarksBreakout Entry Signal Confirmation Tool Used - 선데이타임즈
Quince Therapeutics stock price target lowered to $8 by Citizens JMP - Investing.com South Africa
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - BioSpace
Quince Therapeutics Reports Q2 2025 Financial Results - TipRanks
What makes Quince Therapeutics Inc. stock price move sharplyEarnings Based Stock Performance Forecast - Newser
Custom strategy builders for tracking Quince Therapeutics Inc.Free Trade Ready Stock Watch for Short Term - Newser
Should you hold or exit Quince Therapeutics Inc. nowFree Growth Based Investment Plan Guidance - Newser
Analyzing recovery setups for Quince Therapeutics Inc. investorsMachine Learning Intraday Signal Forecast - Newser
Published on: 2025-08-11 03:02:40 - Newser
New Product Launches: Will They Boost Quince Therapeutics Inc. Stock in 2025Fast Movement Forecast for Trading Success - Newser
Quince Therapeutics Inc. stock prediction for this weekFree Accurate Technical Trend Reversal Picks - Newser
Quince Therapeutics (QNCX) Projected to Post Earnings on Tuesday - Defense World
Can trapped investors hope for a rebound in Quince Therapeutics Inc.Market Downturn Defense Strategy Analysis - Newser
What Fibonacci levels say about Quince Therapeutics Inc. reboundSwing Trade Signal and Price Prediction - Newser
Using data tools to time your Quince Therapeutics Inc. exitFree Stock Market Entry Timing Signals - Newser
Citizens Jmp Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics (NASDAQ:QNCX) Research Coverage Started at Citizens Jmp - Defense World
Quince Therapeutics and the Strategic Partnership with Option Care Health: A Pathway to eDSP Commercialization and Market Expansion - AInvest
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP - The Globe and Mail
Is Quince Therapeutics Inc. a candidate for recovery playTrend Following Ideas with Volume Confirmation - Newser
Quince Therapeutics (NASDAQ:QNCX) Coverage Initiated by Analysts at JMP Securities - Defense World
Exit strategy if you’re trapped in Quince Therapeutics Inc.Free Smart Money Tracking Signal Generator - Newser
Analyst Upgrades and Initiations for Tuesday: Lionsgate Studios, MBX Biosciences, D-Wave Quantum, APA Corporation, and Quince Therapeutics - AInvest
Quince Therapeutics stock initiated with Market Outperform rating at JMP By Investing.com - Investing.com Canada
Quince Therapeutics initiated with an Outperform at Citizens JMP - TipRanks
Quince Therapeutics stock initiated with Market Outperform rating at JMP - Investing.com
Technical Models Detect Momentum Build in Quince Therapeutics Inc.Pattern Detection for Entry Confirmation Enabled - metal.it
What candlestick patterns are forming on Quince Therapeutics Inc.Predictable Income Summary for Long-Term Trades - Newser
Finanzdaten der Quince Therapeutics Inc-Aktie (QNCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Quince Therapeutics Inc-Aktie (QNCX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER |
Aug 29 '24 |
Buy |
0.69 |
77,500 |
53,475 |
766,941 |
| Ryan Charles S. | PRESIDENT |
Aug 20 '24 |
Buy |
0.65 |
48,387 |
31,452 |
122,461 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 21 '24 |
Buy |
0.63 |
30,845 |
19,337 |
296,540 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 20 '24 |
Buy |
0.60 |
5,924 |
3,579 |
265,695 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 19 '24 |
Buy |
0.58 |
2,155 |
1,250 |
259,771 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):